What is Lifesci Capital's Forecast for TCRX Q3 Earnings?

Key Points

• Lifesci Capital forecasts TScan Therapeutics will report earnings of ($0.31) per share for Q3 2025, consistent with the projected full-year earnings of ($1.12) per share.
• The company last reported earnings of ($0.28) per share, matching analysts' expectations and generating revenues of $3.08 million, exceeding expectations of $1.31 million.
• TScan Therapeutics currently has a Moderate Buy consensus rating among analysts, with a target price averaging $7.80, while recent price targets range from $7.00 to $10.00.

TScan Therapeutics, Inc. (NASDAQ:TCRX - Free Report) - Research analysts at Lifesci Capital issued their Q3 2025 earnings per share estimates for TScan Therapeutics in a report issued on Thursday, August 14th. Lifesci Capital analyst S. Slutsky anticipates that the company will post earnings per share of ($0.31) for the quarter. The consensus estimate for TScan Therapeutics' current full-year earnings is ($1.12) per share. Lifesci Capital also issued estimates for TScan Therapeutics' Q4 2025 earnings at ($0.31) EPS.

TScan Therapeutics (NASDAQ:TCRX - Get Free Report) last announced its earnings results on Tuesday, August 12th. The company reported ($0.28) earnings per share for the quarter, meeting the consensus estimate of ($0.28). TScan Therapeutics had a negative return on equity of 63.33% and a negative net margin of 1,964.88%. The business had revenue of $3.08 million during the quarter, compared to analysts' expectations of $1.31 million.

Other equities analysts have also issued research reports about the company. Wedbush reiterated an "outperform" rating and issued a $7.00 price target on shares of TScan Therapeutics in a research report on Tuesday. Wall Street Zen upgraded TScan Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, July 12th. Finally, HC Wainwright decreased their price target on TScan Therapeutics from $15.00 to $10.00 and set a "buy" rating for the company in a research report on Wednesday, May 7th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $7.80.

TScan Therapeutics Trading Up 2.3%

Shares of TCRX stock opened at $1.81 on Friday. The stock has a 50-day simple moving average of $1.67 and a 200 day simple moving average of $1.67. TScan Therapeutics has a fifty-two week low of $1.02 and a fifty-two week high of $6.23. The stock has a market capitalization of $102.43 million, a P/E ratio of -1.66 and a beta of 0.99. The company has a quick ratio of 8.55, a current ratio of 7.06 and a debt-to-equity ratio of 0.18.

Insider Buying and Selling

In other TScan Therapeutics news, major shareholder Lynx1 Capital Management Lp acquired 1,200,000 shares of the firm's stock in a transaction on Tuesday, May 20th. The stock was purchased at an average cost of $1.20 per share, for a total transaction of $1,440,000.00. Following the transaction, the insider owned 7,946,141 shares of the company's stock, valued at $9,535,369.20. The trade was a 17.79% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 4.35% of the company's stock.

Institutional Investors Weigh In On TScan Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Lynx1 Capital Management LP raised its stake in shares of TScan Therapeutics by 2.5% during the 4th quarter. Lynx1 Capital Management LP now owns 5,357,347 shares of the company's stock worth $16,286,000 after purchasing an additional 132,747 shares in the last quarter. BVF Inc. IL raised its stake in shares of TScan Therapeutics by 6.9% during the 2nd quarter. BVF Inc. IL now owns 5,226,074 shares of the company's stock worth $7,578,000 after purchasing an additional 336,600 shares in the last quarter. Checkpoint Capital L.P. raised its stake in shares of TScan Therapeutics by 14.9% during the 1st quarter. Checkpoint Capital L.P. now owns 2,017,650 shares of the company's stock worth $2,784,000 after purchasing an additional 261,663 shares in the last quarter. Aberdeen Group plc raised its stake in shares of TScan Therapeutics by 0.9% during the 1st quarter. Aberdeen Group plc now owns 891,448 shares of the company's stock worth $1,230,000 after purchasing an additional 7,744 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its stake in shares of TScan Therapeutics by 8.5% during the 2nd quarter. JPMorgan Chase & Co. now owns 287,743 shares of the company's stock worth $417,000 after purchasing an additional 22,642 shares in the last quarter. 82.83% of the stock is owned by hedge funds and other institutional investors.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.